Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy

Cancer

Volumn 117, Issue 21, 2011, Pages 5013-5020

  Lipton, Allan ^a   Leitzel, Kim ^a   Ali, Suhail M ^a,b   Carney, Walter ^c   Platek, Greg ^d   Steplewski, Klaudia ^d   Westlund, Ron ^d   Gagnon, Robert ^d   Martin, Anne Marie ^d   Maltzman, Julie ^d  

^a PENN STATE CANCER INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Oncogene Science   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

clinical outcome; ErbB2; HER2 ECD; metastatic breast cancer; response

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80054817785     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26101     Document Type: Article

References (25)

1. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986; 319: 230-234. (Pubitemid 16128786)
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182. (Pubitemid 17231334)
3. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18: 3651-3664.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-712. (Pubitemid 19147683)
5. Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006; 10: 39-50. (Pubitemid 44018087)
6. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP,. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003; 49: 1579-1598. (Pubitemid 37194212)
7. Carney WP, Leitzel K, Ali S, Neumann R, Lipton A,. HER-2/neu diagnostics in breast cancer. Breast Cancer Res. 2007; 9: 207.
8. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002; 20: 1467-1472. (Pubitemid 34260524)
9. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003; 21: 1967-1972. (Pubitemid 46606385)
10. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 2000; 6: 2356-2362. (Pubitemid 30399203)
11. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 1800-1808. (Pubitemid 34273269)
12. Kostler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004; 10: 1618-1624. (Pubitemid 38435551)
13. Sandri MT, Johansson HA, Zorzino L, et al. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer. 2007; 110: 509-517. (Pubitemid 47106138)
14. Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008; 113: 1294-1301.
15. Cameron DA, Stein S,. Drug insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol. 2008; 9: 512-520.
16. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355: 2733-2743. (Pubitemid 46021510)
17. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008; 26: 2999-3005.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006; 100: 229-235. (Pubitemid 44631925)
19. Carney WP,. The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer. Lab Medicine. 2003; 34: 58-64. (Pubitemid 36197260)
20. Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 2005; 7: R436-R443.
21. Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005; 16: 234-239. (Pubitemid 40309302)
22. Lennon S, Barton C, Banken L, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol. 2009; 27: 1685-1693.
23. Finn RS, Gagnon R, Di LA, Press MF, Arbushites M, Koehler M,. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol. 2009; 27: 5552-5558.
24. Witters L, Scherle P, Friedman S, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008; 68: 7083-7089.
25. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol. 2007; 25: 5410-5417. (Pubitemid 350232217)